GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Other Gross PPE

Boundless Bio (Boundless Bio) Other Gross PPE : $5.80 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Other Gross PPE?

Boundless Bio's Other Gross PPE for the quarter that ended in Mar. 2024 was $5.80 Mil.

Boundless Bio's quarterly Other Gross PPE declined from Sep. 2023 ($6.67 Mil) to Dec. 2023 ($6.31 Mil) and declined from Dec. 2023 ($6.31 Mil) to Mar. 2024 ($5.80 Mil).

Boundless Bio's annual Other Gross PPE increased from Dec. 2021 ($3.66 Mil) to Dec. 2022 ($8.71 Mil) but then declined from Dec. 2022 ($8.71 Mil) to Dec. 2023 ($6.31 Mil).


Boundless Bio Other Gross PPE Historical Data

The historical data trend for Boundless Bio's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Other Gross PPE Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Other Gross PPE
3.66 8.71 6.31

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only - 7.88 6.67 6.31 5.80

Boundless Bio Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Boundless Bio (Boundless Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio (Boundless Bio) Headlines

From GuruFocus